PM1009

Phase 2Small molecule

BBiotheus Inc.

PM1009 is one of 8 small molecule programs targeting First-line. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

First-LineNot yet recruiting

First-LinePhase 2

Not yet recruiting

Competition

Competitive Landscape

7 competitors in First-Line

#DrugCompanyPhaseTrials

Targeted Therapy

FFudan University

Phase 2

1 2

PM8002

BBiotheus Inc.

Phase 2

1 3

PD-1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

1 4

Delstrigo

PProfessor Francois Venter

Phase 3

1 5

EGFR-TK Inhibitor

LLuBing

Phase 2

1 6

PM1009

BBiotheus Inc.

Phase 2

1 7

Pariet

Eisai

Preclinical

1 8

Amolin

CChang Gung Memorial Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Not yet recruiting

First-Line

NCT06584071

Clinical

Trials by Indication[1]

Advanced1 trial

A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours

Unknown status·BBiotheus Inc.·Phase 1·NCT05607563·54 enrolled

First-line1 trial

A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

Not yet recruiting·BBiotheus Inc.·Phase 1/2·NCT06584071·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PM1009. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PM1009 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PM1009. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biotheus Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBiotheus Inc.

PM1009

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Advanced1 trial

First-line1 trial

References

Drug Info

Quick Facts

Related News